RxDoctor Payments Data

Bella Zimilevich, MD

Geriatric Medicine · Brooklyn, NYNPI 1972799161

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 30.5% of the total.

$1,571in general payments, 2019–2025

Across 64 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$480
  • Lilly USA, LLC$327
  • Vanda Pharmaceuticals Inc.$303
  • AstraZeneca$158
  • Novo Nordisk$128
  • GSK$53
  • plus $123 from 3 others

What the payments were for

  • Food & beverage$1,571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,571 in reported general payments places this provider in the 85th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$56,894
Medicare patients
60
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide28$51,479
FarxigaDapagliflozin Propanediol45$49,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$26,007
CreonLipase/Protease/Amylase11$25,093
MounjaroTirzepatide17$22,448
JardianceEmpagliflozin16$20,766
EliquisApixaban17$18,523
OzempicSemaglutide11$10,858
Albuterol Sulfate HfaAlbuterol Sulfate49$1,403
Atorvastatin Calcium150$1,318
Metoprolol Succinate53$743
Amlodipine Besylate136$721
Fluticasone Propionate38$504
Rosuvastatin Calcium66$489
Valsartan22$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$327$73,92745 claims
AstraZenecaFarxiga$158$49,54745 claims
GSKTrelegy Ellipta$53$26,00730 claims
AbbVieCreon$46$25,09311 claims
Boehringer IngelheimJardiance$31$20,76616 claims
Novo NordiskOzempic$128$10,85811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →